electroCore Announces Department of Veterans Affairs Sponsored Study of Non-Invasive Vagal Nerve Stimulation (nVNS) in Mild Traumatic Brain Injury (mTBI) and Post-Traumatic Stress Disorder (PTSD)GlobeNewsWire • 09/30/20
electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CVGlobeNewsWire • 09/24/20
electroCore to Present at the HC Wainwright Virtual 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/11/20
electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)GlobeNewsWire • 08/27/20
electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in EnglandGlobeNewsWire • 08/24/20
electroCore, Inc's (ECOR) CEO Dan Goldberger on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/14/20
electroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13GlobeNewsWire • 08/06/20
electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 PatientsGlobeNewsWire • 07/30/20
electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in CephalalgiaGlobeNewsWire • 07/28/20
Correction - electroCore Provides Business Update and Select Financial GuidanceGlobeNewsWire • 07/16/20
ElectroCore's stock rockets in active trading after EUA issued for its gammaCore Saphire CVMarket Watch • 07/13/20
electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 PatientsGlobeNewsWire • 07/13/20